evidence gap is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
The president of the Republic of the Union of Myanmar (Burmese: နိုင်ငံတော်သမ္မတ, MLCTS: nuing ngam tau samma.ta., lit. 'President of the State') is the head of state and head of government of Myanmar. The president chairs the National Defence and Security Council and leads the Union Government (Cabinet), the executive branch of the Myanmar government. The presidency was established in 1948, when Burma gained its independence from the British Empire. During this period, the president was the ceremonial head of state while prime minister is the actual head of government. The presidency was abolished following the 1962 coup d'etat, when Ne Win assumed the powers of both head of state and head of government as the Chairman of the Revolutionary Council and the Revolutionary Government. The 1974 Constitution reintroduced the presidency, to be held by the Chairman of the Council of State. The 1988 coup d'etat again led to the presidency's abolishment, with the Chairman of the State Law and Order Restoration Council (reconstituted in 1997 as the State Peace and Development Council) assuming the functions of the head of state. The 2008 Constitution introduced a presidential system, where the president is both the head of state and government. Thein Sein assumed the presidency in 2011. After the 2015 election, the extraconstitutional post of State Counsellor of Myanmar was created for Aung San Suu Kyi, the leader of the majority party, the National League for Democracy, because she was ineligible for the presidency.
== Examples == DAMPs vary greatly depending on the type of cell (epithelial or mesenchymal) and injured tissue, but they all share the common feature of stimulating an innate immune response within an organism.
=== Short-term effects === Insufflating (snorting) cocaine commonly causes increased mucus production due to irritation and inflammation of the nasal passages. This irritation leads to symptoms such as a runny nose, nasal congestion, and excessive or thickened mucus. Acute exposure to cocaine has many effects on humans, including euphoria, increases in heart rate and blood pressure, and increases in cortisol secretion from the adrenal gland. In humans with acute exposure followed by continuous exposure to cocaine at a constant blood concentration, the acute tolerance to the chronotropic cardiac effects of cocaine begins after about 10 minutes, while acute tolerance to the euphoric effects of cocaine begins after about one hour. With excessive or prolonged use, the drug can cause itching, fast heart rate, and paranoid delusions or sensations of insects crawling on the skin. Cocaine can induce psychosis characterized by paranoia, impaired reality testing, hallucinations, irritability, and physical aggression. Cocaine intoxication can cause hyperawareness, hypervigilance, psychomotor agitation, and delirium. Consumption of large doses of cocaine can cause violent outbursts, especially by those with preexisting psychosis. Acute exposure may induce arrhythmia, including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, and ventricular fibrillation. Acute exposure may also lead to angina, heart attack, and congestive heart failure.
Sources: en.wikipedia.org
=== April === 1 April Biochemists report finishing the complete sequence of the human genome. A study shows that, contrary to widespread belief, body sizes of mammal extinction survivors of the dinosaur-times extinction event were the first to evolutionarily increase, with brain sizes increasing later in the Eocene. 4 April The Intergovernmental Panel on Climate Change (IPCC) releases the third and final part of its Sixth Assessment Report on climate change, warning that greenhouse gas emissions must peak before 2025 at the latest and decline 43% by 2030, in order to likely limit global warming to 1.5 °C (2.7 °F). Researchers announce a new technique for accelerating the development of vaccines and other pharmaceutical products by up to a million times, using much smaller quantities based on DNA nanotechnology. Alzheimer's disease (AD) research progress:A study reports 42 new genes linked to an increased risk of AD. Researchers report a potential primary mechanism of sleep disturbance as an early-stage effect of neurodegenerative diseases. Researchers identify several genes associated with changes in brain structure over lifetime and potential AD therapy-targets (5 Apr).
Treatment should take into account the cause and severity of the condition. If the iron-deficiency anemia is a result of blood loss or another underlying cause, treatment is geared toward addressing the underlying cause. Most cases of iron deficiency anemia are treated with oral iron supplements. In severe acute cases, treatment measures are taken for immediate management in the interim, such as blood transfusions or intravenous iron. For less severe cases, treatment of iron-deficiency anemia includes dietary changes to incorporate iron-rich foods into regular oral intake and oral iron supplementation. Foods rich in ascorbic acid (vitamin C) can also be beneficial, since ascorbic acid enhances iron absorption. Oral iron supplements are available in multiple forms. Some are in the form of pills, and some are drops for children. Most forms of oral iron replacement therapy are absorbed well by the small intestine; however, there are certain preparations of iron supplements that are designed for longer release in the small intestine than other preparations. Oral iron supplements are best taken up by the body on an empty stomach because food can decrease the amount of iron absorbed from the small intestine. The dosing of oral iron replacement therapy is as much as 100–200 mg per day in adults and 3–6 mg per kilogram in children. This is generally spread out as 3–4 pills taken throughout the day. The various forms of treatment are not without possible adverse side effects.
7 July Starmer makes his first visit to Scotland as prime minister, for a meeting with First Minister John Swinney. Lewis Hamilton of Mercedes takes his ninth victory at the British Grand Prix, breaking the record for the most wins at a single circuit and Grand Prix, and the most wins at a driver's home Grand Prix, bringing an end to a 56 winless race streak and making him the first driver to win a race after their 300th Grand Prix start. 8 July The Chancellor, Rachel Reeves, announces new housebuilding targets for England, and the loosening of planning rules to encourage more new homes. The ban on onshore wind in England is lifted. 9 July Minister Jim McMahon tells BBC News that the phrase "levelling-up" will be replaced with "local government" and that his department will now be named the Ministry of Housing, Communities and Local Government. Health Secretary Wes Streeting begins talks aimed at ending a long-running pay dispute with junior doctors in England. Starmer holds his second cabinet meeting, after telling England's regional mayors he will meet with them regularly to help growth across the UK. The first meeting of the 59th Parliament of the United Kingdom takes place. Vacuum manufacturer Dyson announces it is cutting a third of its UK workforce as part of a global restructuring strategy. 10 July Starmer travels to Washington, D.C., his first foreign trip as UK Prime Minister, to attend the 75th NATO summit.
Sources: en.wikipedia.org
Taking a break from training to allow time for recovery. Reducing volume and/or intensity of training. Suitable periodization of training. Splitting the training program so that different sets of muscles are worked on different days. Increase sleep time. Deep-tissue or sports massage of the affected muscles. Self-massage or rub down of the affected muscles. Short sprints with long resting time once the athlete is able to continue with light training.
In Konsumentombudsmannen v Gourmet AB the Court suggested that a total ban for advertising alcohol on the radio, TV and in magazines could fall within article 34 where advertising was the only way for sellers to overcome consumers' "traditional social practices and to local habits and customs" to buy their products, but again the national courts would decide whether it was justified under article 36 to protect public health. Under the Unfair Commercial Practices Directive, the EU harmonised restrictions on restrictions on marketing and advertising, to forbid conduct that distorts average consumer behaviour, is misleading or aggressive, and sets out a list of examples that count as unfair. Increasingly, states have to give mutual recognition to each other's standards of regulation, while the EU has attempted to harmonise minimum ideals of best practice. The attempt to raise standards is hoped to avoid a regulatory "race to the bottom", while allowing consumers access to goods from around the continent.
==== Anemia ==== To combat anaemia, an iron addition to the feed in the form of organic iron compounds or iron sulphate is particularly useful. The iron content in the feed should be slightly above the maintenance requirement of 5 mg/MJ UE. However, the parenteral administration of iron is more potent. If the hematocrit (Hct) nevertheless falls, blood transfusions are indicated. Anabolic steroids Steroids to increase new blood formation are slow-acting in cats and their benefit is questionable. recombinant human erythropoietin may be indicated from a hematocrit < 20%. However, the treatment is expensive and around a third of all cats form antibodies against this substance, which results in anemia that can no longer be treated. With darbepoetin, the risk of antibody formation is apparently significantly lower, it also has a longer plasma half-life and is more potent. Darbepoetin is used when the hematocrit is permanently below 20, the target range is a Hct of 25–35. This is usually achieved after two to three weeks, then the dose can be gradually reduced.
=== Phase 2/3 === Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – smoking withdrawal NFL-101 (tobacco leaf extract) – immunomodulator (smoking vaccine) – smoking withdrawal
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.